The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease

  • Dalene Bott Kitslaar
  • Waldemar E. Wysokinski
  • Robert D. McBaneII
Vascular Disease (R Schainfeld, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Vascular Disease

Opinion statement

The introduction of oral direct coagulation factor inhibitors is dramatically changing the landscape of anticoagulation delivery in patients experiencing or at risk for a thrombotic event. These novel anticoagulants can be particularly attractive for health care providers, as they deliver therapeutic anticoagulation at a fixed dose, require no routine coagulation monitoring, and have few drug interactions and no food restrictions. Herein, we will review the role of these novel anticoagulants for acute venous thromboembolism treatment, primary and secondary venous thromboembolism prevention, and management during the periprocedural period.

Keywords

Novel anticoagulants Rivaroxaban Dabigatran Apixaban Edoxaban Venous thromboembolism treatment (VTE) 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Deitelzweig SB et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86:217–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Heit JA et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Beckman MG et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495–501.PubMedCrossRefGoogle Scholar
  4. 4.
    Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S.PubMedCentralPubMedGoogle Scholar
  7. 7.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Ann Rev Med. 2011;62:41–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Quinlan DJ, Eriksson BI. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Best Pract Res Clin Haematol. 2013;26:171–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Makaryus JN, Halperin JL, Lau JF. Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol. 2013;10:397–409.PubMedCrossRefGoogle Scholar
  12. 12.
    Tun NM, Oo TH. Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis. 2013;2013:1–10.CrossRefGoogle Scholar
  13. 13.•
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52. The major randomized clinical trial comparing dabigatran to warfarin for treatment of VTE in which dabigatran was shown to be non-inferior to warfarin with similar safety profiles.PubMedCrossRefGoogle Scholar
  14. 14.
    Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397–402.PubMedCrossRefGoogle Scholar
  16. 16.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet. 2007;370:949–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, noninferiority trial. Thromb Haemost. 2011;105:721–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–21.PubMedCrossRefGoogle Scholar
  21. 21.••
    Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510. Randomized control trial for treatment of VTE supporting use of rivaroxaban for treatment of VTE leading to a treatment option for patients in addition to conventional therapy.PubMedCrossRefGoogle Scholar
  22. 22.
    Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.PubMedCrossRefGoogle Scholar
  23. 23.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.PubMedCrossRefGoogle Scholar
  28. 28.••
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. Randomized clinical trial using apixaban for treatment of VTE, based on trial anticipate future FDA approval for use of apixaban in treating VTE.PubMedCrossRefGoogle Scholar
  29. 29.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743–53.PubMedCrossRefGoogle Scholar
  31. 31.••
    Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15. Randomized clinical trial using endoxaban for treatment of VTE, based on trial anticipate future FDA approval for use of endoxan in treating VTE.PubMedCrossRefGoogle Scholar
  32. 32.
    van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest. 2006;129:1155–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167:229–35.PubMedCrossRefGoogle Scholar
  34. 34.
    FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate) Available at: http://www.fda.gov/drugs/drugsafety/ucm282724.htm. Accessed 21 Nov 2013.
  35. 35.
    Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32:673–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013;35:262–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct Factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104:1078–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S–50S.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–24.PubMedCrossRefGoogle Scholar
  41. 41.
    McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:442–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Tafur AJ, McBane II R, Wysokinski WE, Litin S, Daniels P, Slusser J, et al. Predictors of major bleeding in periprocedural anticoagulation management. J Thromb Haemost. 2012;10:261–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013;37:241–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, et al. Dabigatran in the periprocedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol. 2013;37:223–31.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Dalene Bott Kitslaar
    • 1
  • Waldemar E. Wysokinski
    • 1
    • 2
  • Robert D. McBaneII
    • 1
    • 2
  1. 1.Division of Cardiovascular MedicineMayo Clinic and FoundationRochesterUSA
  2. 2.Division of Hematology ResearchMayo Clinic and FoundationRochesterUSA

Personalised recommendations